Ionis Pharmaceuticals, Inc.
Compositions and Methods for Modulating MECP2 Expression

Last updated:

Abstract:

Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression. Such compounds and methods are useful to treat, prevent, or ameliorate MECP2 associated disorders and syndromes. Such MECP2 associated disorders include MECP2 duplication syndrome.

Status:
Application
Type:

Utility

Filling date:

23 Aug 2021

Issue date:

21 Jul 2022